Filing Details

Accession Number:
0001209191-20-016416
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-04 20:33:32
Reporting Period:
2020-03-02
Accepted Time:
2020-03-04 20:33:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1503802 Karyopharm Therapeutics Inc. KPTI Pharmaceutical Preparations (2834) 263931704
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1603510 Brett Christopher Primiano C/O Karyopharm Therapeutics Inc.
85 Wells Avenue
Newton MA 02459
Evp, Cbo, Gc & Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-03-02 26,500 $10.39 36,867 No 4 M Direct
Common Stock Disposition 2020-03-02 7,500 $23.50 29,367 No 4 S Direct
Common Stock Disposition 2020-03-02 10,000 $28.00 19,367 No 4 S Direct
Common Stock Disposition 2020-03-02 9,000 $24.00 10,367 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-03-02 26,500 $0.00 26,500 $10.39
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
76,500 2027-01-19 No 4 M Direct
Footnotes
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.04, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.